Kairos Pharma reports interim Phase 2 ENV-105 prostate cancer data showing 17.7-month median progression-free survival

Kairos Pharma reported interim Phase 2 ENV-105 prostate cancer data showing a 17.7-month median progression-free survival versus 2 months in the comparator.

Detected & updated continuously · Source: Nebula